VTH145

VTH145 is a preclinical-stage therapeutic candidate being developed by Verra Therapeutics. It is a peptide-based small protein, likely a modified native peptide (MNP), generated through the company's proprietary platform which focuses on engineering peptides to improve stability and potency. While the specific molecular target and primary indication for VTH145 have not been publicly disclosed in detail, it is part of a broader pipeline targeting inflammatory and fibrotic conditions in cardiovascular and pulmonary health. The candidate is currently in the early stages of development as a preclinical drug candidate.